U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H21NO3.ClH
Molecular Weight 347.8365
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NALORPHINE HYDROCHLORIDE

SMILES

C=CCN1CC[C@@]23[C@@]4([H])C=C[C@@]([H])([C@]2([H])Oc5c(ccc(C[C@]41[H])c53)O)O.Cl

InChI

InChIKey=NAHATSPWSULUAA-ZQGPYOJVSA-N
InChI=1S/C19H21NO3.ClH/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20;/h2-6,12-13,15,18,21-22H,1,7-10H2;1H/t12-,13+,15-,18-,19-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C19H21NO3
Molecular Weight 311.3757
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_12280.html | https://www.ncbi.nlm.nih.gov/pubmed/16433932 | https://www.ncbi.nlm.nih.gov/pubmed/6301606 | doi:10.3181/00379727-77-18904

Nalorphine has a mixed opioid agonist-antagonist properties. Nalorphine inhibits the cholinesterases of mouse brain, bovine erythrocytes and horse serum. It acts on mu-, k- and sigma-opioid receptors. Nalorfin by virtue of the agonistic effect has an analgesic effect but to a much lesser extent than morphine. Initially, before the appearance of a "pure" morphine-naloxone antagonist, nalorphine was used as an antidote for severe respiratory depression and other body function disorders caused by acute poisoning in case of an overdose of morphine, promedol, fentanyl or other narcotic analgesics, or with increased sensitivity to them. At present, nalorphine is practically not used for this purpose. It was replaced by naloxone. Large doses of nalorphine can cause nausea, cramps, drowsiness, headache, mental stimulation.

Originator

Sources: DOI: 10.1021/ja01846a504

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL3198
Sources: doi: 10.3181/00379727-77-18904
1.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Norfin

Approved Use

It is used as an antidote for opiates.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.12 μg/g
2 mg/kg single, subcutaneous
dose: 2 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
NALORPHINE unknown
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.17 μg × h/g
2 mg/kg single, subcutaneous
dose: 2 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
NALORPHINE unknown
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 min
2 mg/kg single, subcutaneous
dose: 2 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
NALORPHINE unknown
Canis lupus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as victim
PubMed

PubMed

TitleDatePubMed
Changes in nalorphine-induced hyperprolactinaemia after bromocriptine or sulpiride administration.
1982
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
1997 Aug
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
1998 Mar
Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.
2005 Aug
Patents

Sample Use Guides

Adults appoint 0,005 - 0,01 g (1 - 2 ml of a 0.5% solution). If the effect is insufficient, the injections are repeated at intervals of 10 to 15 minutes. The total dose should not exceed 0.04 g (8 ml of 0.5% solution).
Route of Administration: Other
In Vitro Use Guide
Maximum stimulation of [35S]GTPyS binding by Nalorphine using a single saturating concentration of ligand (10 uM) was compared with stimulation by DAAMGO (10 uM). Intrinsic activity determined for Nalorphine in C6 glioma cells was 9%.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:52 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:52 UTC 2021
Record UNII
9FPE56Z2TW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NALORPHINE HYDROCHLORIDE
GREEN BOOK   MART.   MI   USP   WHO-DD  
Common Name English
NALORPHINE HCL
Common Name English
17-ALLYL-7,8-DIDEHYDRO-4,5.ALPHA.-EPOXYMORPHINAN-3,6.ALPHA.-DIOL HYDROCHLORIDE
Systematic Name English
NALORPHINE HYDROCHLORIDE CIII
USP-RS  
Common Name English
MORPHINAN-3,6-DIOL, 7,8-DIDEHYDRO-4,5-EPOXY-17-(2-PROPENYL)-(5.ALPHA.,6.ALPHA.)-, HYDROCHLORIDE
Systematic Name English
NALORPHINE HYDROCHLORIDE [MART.]
Common Name English
NALORPHINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
NALORPHINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
NALORPHINE HYDROCHLORIDE CIII [USP-RS]
Common Name English
NALORPHINE HYDROCHLORIDE [MI]
Common Name English
NALORPHINE HYDROCHLORIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
CFR 21 CFR 522.1452
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
Code System Code Type Description
FDA UNII
9FPE56Z2TW
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
CAS
57-29-4
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-321-8
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
DRUG BANK
DBSALT001652
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
MERCK INDEX
M7716
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY Merck Index
EPA CompTox
57-29-4
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
EVMPD
SUB03381MIG
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
ChEMBL
CHEMBL415284
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
NCI_THESAURUS
C76849
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
USP_CATALOG
1452002
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY USP-RS
PUBCHEM
5484366
Created by admin on Fri Jun 25 20:55:52 UTC 2021 , Edited by admin on Fri Jun 25 20:55:52 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY